Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $10.3 million, a 7% increase from $9.6 million in Q2 2024, marking the fourth consecutive quarter of year-over-year growth [13][19] - Adjusted EBITDA improved to negative $800,000, the best quarterly result since going public in mid-2021, compared to negative $2.6 million in Q2 2024 [8][18] - Gross profit increased to $4 million with a gross margin of 38.7%, up from 29.2% in Q2 2024, driven by manufacturing efficiency gains [16][17] Business Line Data and Key Metrics Changes - Lab Essentials revenue was $7.8 million, a 2% increase from $7.6 million in Q2 2024, attributed to an increased number of customers [14] - Clinical Solutions revenue rose to $2.1 million, a 32% increase from $1.6 million in Q2 2024, also due to an increased number of customers [15][16] Market Data and Key Metrics Changes - Revenue from catalog products, which represents about 60% of annual revenue, grew in the low double digits year-over-year, aligning with historical growth rates from 2009 to 2019 [9][10] - The growth in catalog products was driven by key accounts in large pharma and life science tools, indicating above-market growth rates [10] Company Strategy and Development Direction - The company aims to be a leader in essential research reagents and to support emerging therapeutic developers through custom research and clinical grade reagents [9][12] - Inorganic growth opportunities are being pursued, including collaborations and acquisitions to enhance product offerings and operational scale [12][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term outlook for end markets, despite challenges faced by small to mid-sized biotech customers [11][24] - The company reiterated its 2025 total revenue guidance of $39 million to $42 million, expecting continued growth in catalog products while custom products may see lower growth due to macroeconomic conditions [19][20] Other Important Information - The company reduced its headcount by about 40% from its peak, cutting annual operating expenses by approximately $18 million over the past three years [6] - Free cash flow for Q2 2025 was negative $2.3 million, an improvement from negative $3 million in Q2 2024 [18] Q&A Session Summary Question: How has the company managed through headwinds in the biotech funding landscape? - Management noted that while early-stage small to mid-sized biotech companies are struggling, the company has balanced losses with expected spending from larger companies and later-stage therapies [26][27][30] Question: Can you elaborate on the inorganic opportunities and gaps in the product portfolio? - The company is focusing on collaborations with smaller companies and potential acquisitions to fill gaps in upstream products like cell culture media and transfection reagents [31][32] Question: How is the RUO Plus initiative trending? - The initiative is performing as anticipated, providing flexibility for customers transitioning to clinical applications [36] Question: What are the expectations for Clinical Solutions revenue patterns? - Management indicated that revenue in Clinical Solutions can be lumpy, with no significant large orders affecting Q2 results, and that the business is currently in a normal range [38][75] Question: What are the key factors driving customer spending decisions in the current environment? - Customers are looking for predictability and stability, with recent positive engagement suggesting potential recovery in spending [50][51] Question: How has the company's sales force and online presence evolved? - The company has shifted from a reactive to a proactive approach in attracting new customers, contributing to growth despite macroeconomic challenges [56][59] Question: What are the expectations for gross margins in the second half of the year? - Management expects gross margins to remain lower than Q2 but anticipates continued improvements in efficiency and potential upside in the long term [61][66]

Financial Performance - Q2 2025 - Total revenue for Q2 2025 increased by 7% year-over-year, reaching $103 million[20] - Clinical Solutions revenue increased significantly by 32% compared to Q2 2024[21] - Gross margin improved from 292% in Q2 2024 to 387% in Q2 2025[23] - Adjusted EBITDA improved from a loss of $26 million in Q2 2024 to a loss of $08 million in Q2 2025[26] - Free cash flow improved from a negative $30 million in Q2 2024 to a negative $23 million in Q2 2025[28] Revenue Breakdown - 2024 - Catalog products accounted for approximately 60% of total revenue in 2024[14, 15] - Custom products represented about 35% of total revenue in 2024, with biopharma contributing 70% of custom revenue and 25% of total revenue[14, 15] - Other revenue, including services and shipping, made up roughly 5% of total revenue in 2024[14, 15] Customer Migration and Spending - Customers purchasing GMP reagents spent 44 times more annually compared to catalog-only customers in 2024[17] - 58% of 2024 revenue came from custom and/or clinical accounts[17] - 27% of 2024 revenue was generated from Cell and Gene Therapy (CGT) customers[17] 2025 Outlook - The company estimates total revenue between $39 million and $42 million, representing a 7% year-over-year increase at the midpoint[41] - The company is targeting a free cash outflow of less than $12 million for 2025[41] - The company estimates an annualized revenue range of $50 million to $55 million to achieve Adjusted EBITDA break-even[41]

FINANCIAL RESULTS: Q1:2025 SLIDE SUPPLEMENT Nasdaq: TKNO May 8, 2025 • Welcome • Business Highlights and Updates Stephen Gunstream, President and Chief Executive Officer • Financial Results and 2025 Outlook Matt Lowell, Chief Financial Officer • Q&A Forward-looking statements and use of non-GAAP financial measures Today's Agenda © 2025 Alpha Teknova, Inc. ● Financial Results | Q1:2025 ● Slide Supplement May 8, 2025 2 Statements in this presentation about future expectations, plans, and prospects, as well as ...